1Harting R, Venugopal P, Gregory SA, et al. Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma, 2007, 7:406-412. 被引量：1
2Atta J, Chow KU, Weidmann E, et al. Dexa-BEAM as salvage therapy in patients with primary refractory aggressive non-Hodgkin lymphoma. Leuk Lymphoma,2007, 48: 349-356. 被引量：1
4Musolino A, Pert'one MA, Michiara M, et al. Lomustine [chloroethylnitrosourea (CCNU)], ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non- Hodgkin lymphoma. Cancer, 2005, 103: 2109-2117. 被引量：1
6Musolino A, Pert'one MA, Michiara M, et al. Lomustine [chloroethylnitrosourea (CCNU)], ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non- Hodgkin lymphoma. Cancer, 2005, 103: 2109-2117. 被引量：1
